NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. More Details
Imperfect balance sheet with concerning outlook.
Share Price & News
How has NeoGenomics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NEO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: NEO's weekly volatility (6%) has been stable over the past year.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: NEO underperformed the US Life Sciences industry which returned 40.9% over the past year.
Return vs Market: NEO underperformed the US Market which returned 34.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is NeoGenomics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StAnnouncing: NeoGenomics (NASDAQ:NEO) Stock Soared An Exciting 465% In The Last Five Years
1 month ago | Simply Wall StThe President of Pharma Services Division of NeoGenomics, Inc. (NASDAQ:NEO), George Cardoza, Just Sold 50% Of Their Holding
5 months ago | Simply Wall StWe Think That There Are More Issues For NeoGenomics (NASDAQ:NEO) Than Just Sluggish Earnings
Is NeoGenomics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NEO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NEO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NEO is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: NEO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NEO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NEO is overvalued based on its PB Ratio (6.4x) compared to the US Life Sciences industry average (6x).
How is NeoGenomics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NEO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NEO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NEO's revenue (14% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: NEO's revenue (14% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NEO's Return on Equity is forecast to be low in 3 years time (4%).
How has NeoGenomics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NEO is currently unprofitable.
Growing Profit Margin: NEO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NEO is unprofitable, but has reduced losses over the past 5 years at a rate of 44.6% per year.
Accelerating Growth: Unable to compare NEO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (51.4%).
Return on Equity
High ROE: NEO has a negative Return on Equity (-1.3%), as it is currently unprofitable.
How is NeoGenomics's financial position?
Financial Position Analysis
Short Term Liabilities: NEO's short term assets ($942.7M) exceed its short term liabilities ($67.8M).
Long Term Liabilities: NEO's short term assets ($942.7M) exceed its long term liabilities ($582.9M).
Debt to Equity History and Analysis
Debt Level: NEO's debt to equity ratio (63.2%) is considered high.
Reducing Debt: NEO's debt to equity ratio has increased from 22% to 63.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if NEO has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NEO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is NeoGenomics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NEO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NEO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NEO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Mallon (58 yo)
Mr. Mark W. Mallon serves as Chief Executive Officer and Director at NeoGenomics Laboratories, Inc. since April 19, 2021. He serves as Chief Executive Officer and Director at NeoGenomics, Inc. since April ...
Experienced Management: NEO's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: NEO's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NEO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.8%.
NeoGenomics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: NeoGenomics, Inc.
- Ticker: NEO
- Exchange: NasdaqCM
- Founded: 2001
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.652b
- Shares outstanding: 122.37m
- Website: https://www.neogenomics.com
Number of Employees
- NeoGenomics, Inc.
- 12701 Commonwealth Drive
- Suite 9
- Fort Myers
- United States
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers te...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/03 23:16|
|End of Day Share Price||2021/08/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.